Context: Repeated hypoglycemia is associated with hypoglycemia-associated autonomic failure (HAAF), a syndrome of defective counterregulation.
T he Diabetes Control and Complications Trial (DCCT)
demonstrated the benefits of glycemic control vis-à -vis the complications of diabetes (1) . Achievement of near-normal glycemia, however, carries the risk of hypoglycemia. In the DCCT, episodes of biochemical and symptomatic hypoglycemia were more frequent during intensive therapy, and the risk of severe hypoglycemia increased 3-fold (2) . Patients with type 1 diabetes suffer from compromised counterregulatory hypoglycemic responsesviz., blunted glucagon and catecholamine responses, which ultimately result in poor recovery from hypoglycemia (3, 4) . Despite recent advances, imperfect insulin treatment remains the mainstay of therapy and continues to be the source of iatrogenic hypoglycemia. Frequent hypoglycemia is associated with hypoglycemia-associated autonomic failure (HAAF), a deterioration in counterregulation. Clinically, HAAF may also be associated with compromised hypoglycemia awareness (5) . Various studies have shown that a single episode of hypoglycemia in nondiabetic subjects is sufficient to induce HAAF, empha-sizing its clinical relevance to the intensive diabetes management (6, 7) . Altered counterregulation after recurrent/ antecedent experimental hypoglycemia has also been demonstrated in type 1 diabetes (8, 9) , providing a robust physiological model of HAAF in humans. The precise mechanisms of HAAF, however, have not yet been clarified, although central nervous system (CNS) signals that mediate the counterregulatory responses may be of importance in its pathogenesis (10) . Studies in animals and humans demonstrate that various stresses, including hypoglycemia and exercise, are associated with central release of endogenous opioids that, in turn, play a significant role in modulating the autonomic/sympatho-adrenomedullary system (11, 12) . Blockade of opioid receptors with infusion of naloxone enhanced hypoglycemia counterregulation, suggesting that central release of endogenous opioids during hypoglycemia (13) may have suppressive effects on counterregulatory responses. However, it is not known whether blocking the effects of endogenous opioids during antecedent hypoglycemia can prevent the development of HAAF (i.e. normalize the counterregulatory responses to subsequent hypoglycemia). Based on our prior data that the counterregulatory response to hypoglycemia can be pharmacologically modulated in humans (14, 15) , we hypothesized that blocking the effects of endogenous opioids with naloxone during recurrent hypoglycemia may prevent HAAF and identify a novel mechanism for further study.
Subjects and Methods

Subjects
We studied eight nondiabetic volunteers (five men, three women; age 28 Ϯ 3 yr; body mass index, 24.2 Ϯ 2.1 kg/m 2 ; glycosylated hemoglobin, 5.6 Ϯ 0.6%). All were in good health, taking no medications, and had no family history of diabetes. Each participated in three sets of studies in random order, with an interval of 5 wk between each set of studies. All studies were performed after an overnight fast.
Every set of studies consisted of 2 consecutive days (d 1 and d 2). Day 2 was identical in all studies and included a stepped hyperinsulinemic hypoglycemia clamp, with quantification of hormonal responses and glucose kinetics. Day 1 in each set of studies consisted of one of the following: 1) two 90-min hyperinsulinemic hypoglycemia clamps (NϪ); 2) two 90-min hyperinsulinemic hypoglycemia clamps with coinfusion of naloxone (Nϩ); or 3) two 90-min hyperinsulinemic euglycemia clamps (C) with no other infusions. This design enabled us to examine the counterregulatory responses and glucose kinetics during stepped hypoglycemia clamps (d 2), after each experimental manipulation performed on d 1. To examine whether naloxone on d 1 could have directly influenced the counterregulatory responses on d 2, we performed an additional set of control studies as follows: d 1 was identical to the control studies but with concomitant naloxone infusion (Cϩ). We performed this additional control after analyzing the results of the above three protocols that demonstrated that naloxone infusion on d 1 had a significant effects on d 2 hypoglycemia counterregulation. Thus, these additional control experiments (Cϩ) were performed 12 months after the completion of the NϪ, Nϩ, and C studies.
Informed written consent was obtained in accordance with policy of the Committee on Clinical Investigations of the Albert Einstein College of Medicine.
Procedures
Subjects were admitted to the Clinical Research Center for each experiment.
Day 1
At 0700 h on the study day, all subjects had two indwelling cannulae inserted, one placed in an antecubital vein for infusions and the second placed in a retrograde fashion in a distal hand vein of the contralateral forearm for blood sampling. To obtain arterialized venous blood samples, this hand was maintained at 65 C in a thermoregulated sleeve. At t ϭ Ϫ30 min, a constant insulin infusion (Humulin Regular; Eli Lilly, Indianapolis, IN) was initiated at a rate of 1 mU/kg ⅐ min, and a variable infusion of 20% dextrose was administered to maintain the plasma glucose concentration at 60 mg/dl (NϪ) for a duration of 90 min. Blood samples were collected at 5-min intervals for measurements of plasma glucose. At the end of the 90-min clamp, insulin infusion was stopped, the subjects received a small snack (15 g of carbohydrate), and their plasma glucose was maintained at euglycemia by the use of an exogenous dextrose infusion (as needed) for an additional 2 h. At that point, insulin was restarted at a rate of 1 mU/kg ⅐ min, and a variable infusion of 20% dextrose was administered for a second 90-min hyperinsulinemic-hypoglycemic (NϪ) clamp. After completion of the second 90-min clamp, subjects consumed a large meal, had a bedtime snack, and were admitted for an overnight fast. All subjects received 5 ml/kg body water of 2 H 2 O (99.9% 2 H; Isotec, Miamisburg, OH), divided into three equal portions and given at 2000, 2300, and 0300 h. Additional water ingested during the fast was enriched to 0.5% with 2 H 2 O to prevent dilution of the isotopic steady state. The second set of studies was similar; however, naloxone (Narcan; Du Pont Pharmaceuticals, Wilmington, DE) was administered as a primed (4 g/kg) continuous (0.4 g/kg ⅐ min) infusion beginning at t ϭ Ϫ30 min and continued throughout each of the hypoglycemia periods of the d 1 hypoglycemia clamps (Nϩ). During the interval between the clamps, naloxone infusion was discontinued.
In the third set of studies (control), d 1 was similar to NϪ, however plasma glucose was maintained at euglycemia during the two 90-min hyperinsulinemic clamps (C).
In the fourth set of studies (Cϩ), d 1 consisted of euglycemia during the two 90-min hyperinsulinemic clamps, together with naloxone (Narcan; Du Pont Pharmaceuticals) administered as a primed (4 g/kg) continuous (0.4 g/kg ⅐ min) infusion beginning at t ϭ Ϫ30 min and continued throughout each of the two euglycemic periods. During the interval between the clamps, naloxone infusion was discontinued. [3- 3 H]glucose was initiated with a bolus of 21.6 Ci, followed by continuous infusion of 0.15 Ci/min for the entire period of study. The specific activity of infused dextrose was kept equivalent to plasma glucose specific activity by addition of [3- 3 H]glucose to the infusate (16) . At t ϭ 0 min, a primed-continuous infusion of insulin was initiated at a rate of 0.5 mU/kg ⅐ min throughout the study, and a variable infusion of 20% dextrose was begun to maintain the plasma glucose concentration at 90 mg/dl for 50 min (step 1 of the clamp). At t ϭ ϩ50 min and every 50 min thereafter, the plasma glucose concentration was decreased by 10 mg/dl decrements for 50 min each by reducing the dextrose infusion rate accordingly. Plasma glucose was clamped at the desired range by varying the dextrose infusion according to plasma glucose measured at 5-min intervals with targets of 90, 80, 70, and 60 mg/dl.
Fasting blood for glycosylated hemoglobin was collected on the morning of each clamp study. During the clamps on d 2, blood samples were obtained for the determinations of plasma insulin, C-peptide, glucagon (collected in heparin-trasyloltreated tubes), epinephrine, and norepinephrine (collected in glutathione-treated tubes), ␤-endorphin (collected in EDTA-treated tubes), and cortisol, as well as for glucose kinetics and 2 H enrichment of the hydrogen bound to C2 and C5 of blood glucose (for gluconeogenesis calculations). Symptoms of hypoglycemia were not measured.
Analytical methods
Plasma glucose was measured with a Beckman glucose analyzer (Beckman Coulter, Fullerton, CA), using the glucose oxidase method. Plasma [3- 3 H]glucose radioactivity was measured in duplicate on the supernatants of barium hydroxide-zinc sulfate precipitates of plasma samples, after evaporation to dryness to eliminate tritiated water.
The methods for measurement of plasma insulin, C-peptide, glucagon, cortisol, and their intra-and interassay variations have been previously reported (17) . Plasma ␤-endorphin was measured using ELISA. Plasma epinephrine and norepinephrine levels were determined using the radioenzymatic assay described by Evans et al. (18) .
H O method
Body water was calculated as 50% of body weight in women and 60% in men (19) . Enrichment of the hydrogen at C2 and C5 of blood glucose was determined by procedures previously described (20) . Briefly, blood was deproteinized and deionized, followed by glucose extraction. The resulting glucose was derivatized into monoacetone glucose (MAG) for nuclear magnetic resonance (NMR) analysis. The MAG sample was dissolved in 120 ml deuterium-depleted water and 420 ml HPLC acetonitrile in a 5-mm NMR tube. A 2 H NMR spectrum was collected at 14.1 T (92 MHz for 2 H) on a Brucker DRX600 system (Brucker BioSpin Corporation, Billerica, MA) equipped with a 5-mm deuterium probe with the ability to do 1 H decoupling and 19 F lock and with a z-gradient. Deuterium was tuned to the 2 H carrier frequency. Shimming was performed on the 1 H signal using the automated gradient shimming routine.
1 H Waltz-16 decoupling was used during acquisition to remove proton-deuterium J coupling. Data were collected over a spectral width of 1.8 KHz at 47 C using the 90-degree pulse, at 1.1-sec acquisition time and an average of 5000 -10,000 acquisition over 2-4 h. Peak areas were analyzed using the curve-fitting routine supplied with the NUTS PC-based NMR spectral analysis program (Acorn NMR Inc., Fremont CA). Given that the acquisition time was 1.1 sec and the longest T1 of any deuteron in MAG is less than 0.25 sec, no postacquisition correction of peak areas was necessary (21) .
Analyses
The data are presented as the mean Ϯ SEM. Steele's equation was used for calculation of glucose turnover as described (22) . Values for endogenous glucose production (EGP) and glucose uptake, obtained at 10-min intervals, were averaged over the final 30-min of each glucose step. The glycemic threshold for activation of a particular hormone was calculated as the glycemic level at which there was an increase of more than 2 SD values above the basal concentration (15) . Statistical analyses were performed using repeated measures ANOVA for multiple comparisons and paired Student's t test for comparing between two means (same subject) before and after an intervention (naloxone infusion). A value of P Ͻ 0.05 was considered significant.
Results
All results relate to the stepped hypoglycemia clamp studies performed on d 2.
Plasma glucose levels and glucose infusion rates (Fig. 1)
Plasma glucose concentrations during the clamps (NϪ, Nϩ, C, and Cϩ) are shown in Fig. 1A . Plasma glucose concentrations at t ϭ 0 were 95 Ϯ 3 mg/dl in the NϪ studies, 94 Ϯ 2 mg/dl in the Nϩ studies, 97 Ϯ 4 mg/dl in the C, and 95 Ϯ 5 mg/dl in the Cϩ studies [P ϭ not significant (NS)]. No significant difference was noted between all studies during the 90, 80, and 70 mg/dl target glucose steps; however, during the 60 mg/dl target glucose step, plasma glucose could not be decreased to less than 64 Ϯ 1 mg/dl in the Nϩ, 65 Ϯ 1 mg/dl in the C, and 64 Ϯ 2 mg/dl in the Cϩ studies. The higher plasma glucose levels in the Nϩ, C, and Cϩ studies during this glucose step occurred despite the fact that the glucose infusion was discontinued and coincided with elevated plasma concentration of epinephrine, norepinephrine, and glucagon (see below).
Glucose infusion rates are depicted in Fig. 1B . During the first (90 mg/dl) and second (80 mg/dl) glucose steps, average glucose infusion rates were comparable in all studies (1.3 Ϯ 0.2 mg/kg ⅐ min in the NϪ, 1.3 Ϯ 0.2 mg/ kg ⅐ min in the Nϩ, 1.4 Ϯ 0.2 mg/kg ⅐ min in the C, and 1.3 Ϯ 0.3 mg/kg ⅐ min in the Cϩ studies; P ϭ NS). However, during the 70 mg/dl glucose step, the mean rate of glucose infusion was lower in the Nϩ, C, and Cϩ studies (0.8 Ϯ 0.2, 0.9 Ϯ 0.1, and 0.8 Ϯ 0.1 mg/kg ⅐ min, respectively, vs. 1.6 Ϯ 0.2 mg/kg ⅐ min in the NϪ studies; P ϭ 0.01). During the 60 mg/dl glucose step, the average glu-
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cose infusion rate was also significantly lower (0.1 Ϯ 0.1 mg/kg ⅐ min) in the Nϩ, C, and Cϩ studies vs. 1.3 Ϯ 0.2 mg/kg ⅐ min in the NϪ studies (P Ͻ 0.001). These data complement our findings suggesting suppressed hypoglycemia counterregulation in the NϪ studies compared with the Nϩ and both control studies (C and Cϩ).
Plasma insulin and C-peptide concentrations (Fig. 2)
Basal plasma insulin concentrations were nearly identical in all studies, averaging 5.9 Ϯ 0.8 U/ml in the NϪ, 6.3 Ϯ 0.5 U/ml in the Nϩ, 5.5 Ϯ 0.8 U/ml in the C, and 6.2 Ϯ 0.9 U/ml in the Cϩ studies (P ϭ NS). Similarly, there was no significant difference in plasma insulin concentration during all clamp steps averaging 52.3 Ϯ 4.2 U/ml in the NϪ, 51.7 Ϯ 1.4 U/ml in the Nϩ, 53.7 Ϯ 1.0 U/ml in the C, and 48.8 Ϯ 3.3 U/ml in the Cϩ studies ( Fig. 2A) . Plasma C-peptide concentrations were comparable in all studies at baseline (1.6 Ϯ 0.2, 1.3 Ϯ 0.4, 1.5 Ϯ 0.4, and 1.3 Ϯ 0.3 ng/ml in the NϪ, Nϩ, C, and Cϩ studies, respectively; P ϭ NS). C-peptide values remained very similar during the clamp, suppressed in all studies to 0.2 Ϯ 0.03 ng/ml at the hypoglycemic nadir, at t ϭ 200 min (Fig. 2B ).
Counterregulatory hormones (Fig. 3) During the 90 and 80 mg/dl glucose steps, plasma epinephrine concentrations remained near or at basal values and were similar in all studies (35 Ϯ 12, 37 Ϯ 14, 38 Ϯ 15, and 34 Ϯ 18 pg/ml in the NϪ, Nϩ, C, and Cϩ studies, respectively, P ϭ NS). Further reduction in plasma glucose to 70 and 60 mg/dl was associated with appropriate increases in plasma epinephrine in the control studies (C and Cϩ) to 810 Ϯ 94 and 765 Ϯ 110 pg/ml, respectively (P ϭ NS). However, in the NϪ studies, plasma epinephrine was only modestly increased to 374 Ϯ 71 pg/ml (P Ͻ 0.01 vs. C and Cϩ), demonstrating blunting of epinephrine response after antecedent hypoglycemia. Finally, in the Nϩ studies, the plasma epinephrine increase was comparable to that in control studies (852 Ϯ 82 pg/ml), suggesting normalization of epinephrine release despite recurrent antecedent hypoglycemia. The amplification of the epinephrine response in the Nϩ studies was demonstrated by the plasma glucose needed to trigger epinephrine release (higher threshold for epinephrine release) as well as by significantly greater peak and plateau levels of plasma epinephrine that were similar to the control studies (Fig. 3A and Table 1 ). 
FIG. 2 . Plasma insulin concentrations (A) and C-peptide concentrations (B) in the Nϩ (f), NϪ (E), C (‚), and Cϩ (ϫ) on d 2 of the studies. J Clin
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Basal and stimulated plasma norepinephrine concentrations were equivalent during the 90 and 80 mg/dl glucose steps in all studies (Fig. 3B) . However, release of norepinephrine was significantly blunted in the NϪ studies during the 70 and 60 mg/dl glucose steps, and the threshold for norepinephrine release occurred at a significantly lower plasma glucose concentration. The threshold for release and peak levels of norepinephrine were no different in controls (C and Cϩ) and Nϩ studies, suggesting correction of the blunted norepinephrine response after recurrent hypoglycemia by naloxone administration (Fig.  3B and Table 1 ).
Plasma glucagon was equivalent in all studies during the 90 and 80 mg/dl glucose steps (Fig. 3C ), but the increase in glucagon was blunted in the NϪ studies during the 60 mg/dl glucose step (71 Ϯ 9 pg/ml in the NϪ vs. 93 Ϯ 4 and 89 Ϯ 5 pg/ml in the C and Cϩ studies, respectively; P Ͻ 0.01 for both). Naloxone administration, however, restored the glucagon response to that observed in control studies (98 Ϯ 7 pg/ml), with normalization of both the amplitude and glycemic threshold for glucagon release (Table 1) .
Finally, plasma cortisol levels were similar in all studies (Fig. 3D ) and unaffected by either antecedent hypoglycemia or antecedent naloxone.
Glucose kinetics and fractional rates of gluconeogenesis (Fig. 4) Mean fasting EGP, measured at the end of the 120 min of tracer infusion (t ϭ 0), was similar in all studies (1.8 Ϯ 0.2, 1.9 Ϯ 0.2, 1.9 Ϯ 0.1, and 2.0 Ϯ 0.3 mg/kg ⅐ min in the NϪ, Nϩ, C, and Cϩ studies, respectively; P ϭ NS). During the 90 and 80 mg/dl glucose steps, EGP was equally suppressed by approximately 65% compared with baseline across all studies. During the next two clamp steps (70 and 60 mg/dl), EGP rose by 11 and 24% from nadir, respectively, in the NϪ studies, showing only modest EGP recovery. In contrast, EGP rose by 154 and 167% from nadir, respectively, in the Nϩ studies (P Ͻ 0.001) and to a similar extent (141 and 163%, and 158 and 171%, respectively; P Ͻ 0.001) in the C and Cϩ studies, demonstrating normalization of EGP recovery in the Nϩ studies to that observed during the control studies (C and Cϩ, Fig. 4A ). Glucose disposal rates (Rd) were similar before insulin infusion in all studies and increased equally with the initiation of insulin infusion by approximately 64% from baseline (to 3.4 Ϯ 0.2, 3.2 Ϯ 0.3, 3.1 Ϯ 0.4, and 3.5 Ϯ 0.5 mg/kg ⅐ min in the NϪ, Nϩ, C, and Cϩ studies, respectively; P ϭ NS, during the 80 mg/dl glucose step). Subsequently, during the 70 and 60 mg/dl glucose steps, glucose Rd decreased by approximately 15% in the NϪ studies, and by 48, 51, and 53% in the Nϩ and control (C and Cϩ) studies, respectively (P Ͻ 0.05), promoting glucose recovery in the Nϩ studies similar to the controls (Fig. 4B) .
The contribution of gluconeogenesis to EGP averaged 44.2 Ϯ 11.9% in the NϪ, 50.0 Ϯ 8.8% in the Nϩ, and 48.7 Ϯ 5.7% in the C studies before the initiation of the clamps (P ϭ NS), and decreased significantly to 37.1 Ϯ 7.4, 34.6 Ϯ 5.2, and 32.2 Ϯ 3.9%, respectively (P Ͻ 0.05, vs. baseline for all), at the 60 mg/dl glucose step, however, with no significant differences between the three protocols. Glycogen turnover measurements were not performed in the Cϩ studies.
Plasma ␤-endorphin levels ( Table 2) On d 1, plasma ␤-endorphin levels at baseline averaged 2.5 Ϯ 0.8, 5.1 Ϯ 1.3, 4.3 Ϯ 1.8, and 2.7 Ϯ 1.4 ng/ml in the NϪ, Nϩ, C, and Cϩ studies, respectively (P ϭ NS). At the end of d 1 experiments, plasma ␤-endorphin concentrations increased significantly in the hypoglycemia studies (16.7 Ϯ 2.3 and 14.4 Ϯ 3.6 ng/ml in the NϪ and Nϩ, respectively; P Ͻ 0.001 in both), however, in the control (C and Cϩ) studies, plasma ␤-endorphin levels did not change significantly (5.3 Ϯ 1.8 and 3.7 Ϯ 2.2 ng/ml, respectively; P ϭ NS).
On d 2, plasma ␤-endorphin levels at baseline averaged 2.4 Ϯ 1.3, 4.2 Ϯ 0.9, 3.1 Ϯ 0.6, and 2.6 Ϯ 1.5 ng/ml in the NϪ, Nϩ, C, and Cϩ studies, respectively (P ϭ NS). At the end of the hypoglycemia clamp, plasma ␤-endorphin concentrations increased significantly in all studies to 11.8 Ϯ 2.5, 15.2 Ϯ 2.7, 13.8 Ϯ 3.3, and 14.4 Ϯ 3.7 ng/ml in the NϪ, Nϩ, C, and Cϩ studies, respectively (P ϭ NS between studies; P Ͻ 0.001 vs. baseline in all studies).
Discussion
Our data demonstrate that in nondiabetic humans, two episodes of mild hypoglycemia (ϳ60 mg/dl) are sufficient to induce deterioration of the counterregulatory response to hypoglycemia on the following day. Compared with antecedent hyperinsulinemic euglycemia clamps (controls), the counterregulatory response in the NϪ studies was characterized by lower epinephrine, norepinephrine, and glucagon responses, with parallel defects in glucose kinetics and impaired glucose recovery. These findings support previous reports demonstrating experimental HAAF using similar designs (6, 8, 9, 23, 24) . Most importantly, we found that an opioid receptor blockade during d 1 hypoglycemia completely prevented the deterioration of the counterregulatory response to hypoglycemia on d 2. Epinephrine, norepinephrine, and glucagon concentrations and the corresponding glucose recovery rates in these studies were comparable to control studies, demonstrating no deterioration in the counterregulatory systems that are used as surrogate evidence of autonomic failure (i.e. HAAF).
For the control studies [euglycemia on d 1 (C) and euglycemia with concomitant naloxone on d 1 (Cϩ)], we used identical clamps to exclude any potential effects of hyperinsulinemia. Thus, plasma insulin concentrations during all studies were comparable. Furthermore, the fact that the counterregulatory responses were identical in the C and Cϩ studies indicates that naloxone infusion per se, in the absence of hypoglycemia, had no influence on the counterregulatory responses to subsequent hypoglycemia (d 2).
The stepped hypoglycemia clamps (on d 2) were identical in all studies with the exception that during the final (60 mg/dl) step plasma, glucose could not be further decreased in the Nϩ and control studies because glucose infusion had been already terminated. This may be explained by the fact that adequate glucose counterregulation had occurred. We intentionally chose a modest insulin infusion rate (0.5 mU/kg ⅐ min) to only partially suppress EGP during the hypoglycemic clamps, and this enabled us to quantify EGP recovery with counterregulation. In parallel with the changes in counterregulatory hormones, we observed the decrease in EGP and a corresponding increase in glucose disposal (Rd) induced by HAAF in the NϪ studies. In contrast, the increase in the counterregulatory responses in the Nϩ and control studies resulted in recovery of the suppressed EGP (due to hyperinsulinemia) and a decrease in Rd-fluxes that are responsible for recovery from hypoglycemia. Thus, these findings further demonstrate that the increase in counterregulation in the Nϩ studies was associated with normalization of hypoglycemia recovery.
To examine whether specific defects in the counterregulatory responses to hypoglycemia in HAAF are associated with abnormal glycogenolysis/gluconeogenesis during hypoglycemia recovery, we used the 2 H 2 O method. The decrease in the contribution of gluconeogenesis to EGP during hypoglycemia recovery supports our and others' previous studies showing that glycogen breakdown is the initial source for glucose-6-phosphate for EGP during the first several hours of hypoglycemia (25, 26) . Although the recovery from hypoglycemia was defective in the NϪ studies, the distribution in the pathways responsible for the increase in EGP (i.e. glycogen breakdown vs. gluconeogenesis) did not differ.
Extensive research on the biology of endogenous opioids has provided a framework through which the current studies can be viewed (27) . Opioid receptor activation occurs in response to a variety of stressors including hypoglycemia (11, 13) and exercise (28) , resulting in increased CNS release of endogenous opioids. The release of endogenous opioids is associated with inhibition of the central component of the sympatho-adrenomedullary system, principally by -and -receptor activation (29) , whereas opioid antagonists enhance catecholamine release (30) . In light of our results, we propose a heretofore unappreciated mechanism that may explain the development of HAAF after repeated hypoglycemia, and we suggest that acute hypoglycemia-induced CNS -opioid receptor activation results in an alteration of its activity, which ultimately results in a decrease in the sympathoadrenal response.
In vivo studies in animals and humans demonstrate that opioid receptor blockade with naloxone during hypoglycemia resulted in an enhanced counterregulatory response (31) and a significant increase in EGP (13) . Our study indicates that the effect of blocking endogenous opioids with naloxone is prolonged and disrupts normal counterregulatory responses to hypoglycemia the following day. However, because naloxone infusion during euglycemia (d 1) had no effect on d 2 counterregulation (Cϩ studies), prevention of HAAF with naloxone administered during antecedent hypoglycemia is not due to a carryover effect of the drug. The fact that plasma ␤-endorphin concentrations increased during hypoglycemia supports other studies that demonstrate increases in plasma ␤-endorphin with stresses including hypoglycemia and minimal variations in peripheral plasma ␤-endorphin concentrations with naloxone infusion (32, 33) . Furthermore, our observation of nearly identical cortisol concentrations in all protocols suggests either that naloxone was infused at an insufficient concentration to induce an increase in cortisol or that there was a differential effect on the counterregulatory hormonal response. Interestingly, the effect of naloxone infusion on glucagon release during subsequent hypoglycemia suggests that glucagon secretion is mediated centrally, at least in part. Although there is considerable evidence that glucagon release during hypoglycemia is modulated at the islet level, several studies have shown that CNS manipulations (e.g. ventromedial hypothalamus) can affect glucagon secretion (reviewed in Ref. 34) , suggesting the possibility of redundant regulation.
In summary, our data demonstrate that HAAF induced by antecedent hypoglycemia in nondiabetic subjects was prevented by opioid receptor blockade. Accumulating reports clearly demonstrate the beneficial effects of meticulous glycemic control in patients with diabetes (1, 35) . Such a therapeutic approach, however, carries a significant risk for developing recurrent hypoglycemia and HAAF (4), conditions that are associated with increased morbidity and mortality. Although it has been previously shown that meticulous avoidance from hypoglycemia can partially reverse HAAF (36) , our data demonstrate that HAAF may be preventable pharmacologically. Further studies are required to examine whether opioid receptor blockade can prevent HAAF in patients with diabetes and whether other delivery methods (that can be used clinically) for opioid receptor blockade drugs have similar effects.
